Myotonic dystrophy (Steinert disease)Myotonic Dystrophy (Steinert Disease / DM1 / DM2)
📋 Contents and key points
1. History
The clinical description of myotonic dystrophy was first reported independently in 1909 by Hans Gustav Wilhelm Steinert of Germany and by Frederick Batten and Herbert Gibb of the United Kingdom. Steinert systematically described a clinical syndrome in which myotonia and muscular atrophy coexist, and it later came to be called 'Steinert disease' after him. Until the mid-20th century, classification based on the clinical phenotype predominated. In 1936, Caughey and Myrianthopoulos published a systematic clinical description, and it was gradually revealed to be a multiorgan disease including ophthalmic, cardiac, and endocrine involvement. In 1992, Brook et al. first identified an abnormal expansion of a CTG trinucleotide repeat sequence in the 3'UTR region of the DMPK gene on the long arm of chromosome 19 as the cause of DM1. This became the starting point of a new pathogenic concept, RNA toxicity due to repeat expansion. Subsequently, in 2001, Liquori et al. identified a CCTG repeat expansion within intron 1 of the CNBP gene on chromosome 3 as the cause of myotonic dystrophy type 2 (DM2). DM2 was confirmed to be the same disease as the clinical group formerly called proximal myotonic myopathy (PROMM, Proximal Myotonic Myopathy) or Ricker disease. Since the 2000s, the mechanism of aberrant splicing through sequestration of MBNL (Muscleblind-like) proteins and hyperactivation of CELF (CUGBP/Elav-like family) proteins has been studied in depth, establishing the current pathogenic model.
2. Causes
Myotonic dystrophy is an autosomal dominant genetic disease caused by abnormal expansion (dynamic mutation) of trinucleotide or tetranucleotide repeat sequences within the noncoding regions of two independent genes.
- DM1 (DMPK gene, 19q13.32): The number of CTG repeats in the 3'UTR of the DMPK (Dystrophia Myotonica Protein Kinase) gene expands from normal (5–37 repeats) to the pathological range (≥50 repeats; thousands in the severe congenital form). The repeat size roughly correlates with phenotypic severity: the more repeats, the earlier the age of onset and the more severe the symptoms.
- DM2 (CNBP gene, 3q21.3): The number of CCTG repeats in intron 1 of the CNBP (Cellular Nucleic Acid-Binding Protein) gene expands from normal (fewer than 26 repeats) to the pathological range (75–11,000 repeats). The correlation between repeat number and phenotype is less clear in DM2 than in DM1.
In both types, the core of pathogenesis is an RNA toxicity mechanism in which transcripts containing the abnormal repeat sequences (CUG or CCUG repeat RNA) accumulate in the nucleus and interact abnormally with specific RNA-binding proteins, causing aberrant splicing. Reduction of the DMPK protein itself (haploinsufficiency) and suppressed expression of adjacent genes (SIX5, etc.) are also known to contribute to some phenotypes.
3. Genetics
Both DM1 and DM2 follow an autosomal dominant mode of inheritance. Genetic anticipation, in which the repeat number expands further when transmitted from a parent carrying the mutation to a child, is prominent. In DM1 in particular, maternal transmission tends to result in congenital myotonic dystrophy (CDM), which is associated with very large CTG expansions of hundreds to thousands of repeats.
DM1 shows somatic mosaicism, with repeat numbers differing between tissues. The repeat number in leukocytes is smaller than in skeletal or cardiac muscle, so clinical severity may be underestimated. In DM2, the range of repeat number variation is very wide (up to about 11,000 CCTG), genetic anticipation is less pronounced than in DM1, and no congenital form has been reported.
| Characteristics | DM1 | DM2 |
| Causative gene | DMPK (19q13.32) | CNBP (3q21.3) |
| Location of repeat sequence | CTG (3'UTR) | CCTG (intron 1) |
| Normal repeat number | 5–37 repeats | <26 repeats |
| Pathological repeat number | ≥50 repeats (premutation: 38–49) | 75–11,000 repeats |
| Genetic anticipation | Prominent (especially maternal) | Relatively mild |
| Occurrence of congenital form | Yes (with maternal transmission) | Not reported |
| Distribution of main muscles involved | Distal predominance | Proximal predominance |
4. General epidemiology
Myotonic dystrophy is the most common hereditary muscle disease in adults. The worldwide prevalence of DM1 is estimated at about 1/8,000–1/20,000, with wide regional variation. In the Saguenay-Lac-Saint-Jean region of Quebec, Canada, the prevalence is reported to reach about 1/550 due to a founder effect. In contrast, prevalence is relatively low in some regions of Asia and Africa.
The prevalence of DM2 is known to be lower than that of DM1, but because symptoms are mild and diagnosis is difficult, it is likely to be underdiagnosed in reality. Some European countries such as Germany and Finland have reported a DM2 prevalence similar to or higher than that of DM1. In Korea, accurate epidemiological data are limited, but according to rare disease registry data, myotonic dystrophy accounts for a considerable proportion of congenital muscle diseases. Incidence is equal in men and women without sex differences, but in the clinical phenotype, frontal balding and male infertility are prominent in men, and pregnancy complications (abnormal uterine contractions, prolonged labor, fetal abnormalities) are important clinical problems in women.
5. Pathophysiology
The pathogenesis of myotonic dystrophy is explained by a 'gain-of-function RNA toxicity' mechanism. CUG repeat RNA transcribed from the mutant allele of the DMPK gene (DM1) or CCUG repeat RNA transcribed from the CNBP gene (DM2) forms aggregates (nuclear foci) within the cell nucleus.
These abnormal RNA aggregates sequester the RNA-binding protein MBNL1 (Muscleblind-like 1), causing loss of its normal splicing regulatory function. At the same time, the CELF1 (CUGBP Elav-like family member 1) protein is hyperactivated through phosphorylation. These two changes abnormally shift the splicing of many pre-mRNAs to fetal isoforms, leading to dysfunction in multiple tissues.
- Muscle: Fetal-type splicing of the ClC-1 (CLCN1) chloride channel → increased membrane excitability → myotonia
- Heart: Aberrant splicing of SCN5A and TNNT2 → conduction defects, arrhythmias
- Pancreas/metabolism: Aberrant splicing of INSR (insulin receptor) → insulin resistance, increased diabetes risk
- Brain: Aberrant splicing of MAPT and APP → cognitive decline, hypersomnia
- Eye: Aberrant splicing of related proteins → posterior subcapsular cataract
6. Symptoms
Myotonic dystrophy is a multisystem disease; in addition to musculoskeletal symptoms, various organs such as the heart, eyes, endocrine system, and central nervous system are involved.
Musculoskeletal system
- Myotonia: Delayed relaxation after voluntary muscle contraction. Symptoms such as difficulty opening the hand after gripping an object or releasing a clenched fist. Worsens with cold or fatigue. More prominent in DM1 and relatively mild in DM2.
- Weakness and muscle atrophy: In DM1, involvement of distal muscles (forearm, ankle dorsiflexors, finger extensors) and facial and neck muscles is characteristic. In DM2, involvement of proximal muscles (quadriceps, hip flexors) predominates. Foot drop may occur due to distal lower-limb weakness.
- Swallowing impairment: Dysphagia due to involvement of the pharyngeal and esophageal muscles. A cause of aspiration pneumonia.
- Respiratory muscle weakness: Respiratory failure may develop due to involvement of the diaphragm, intercostal muscles, and upper airway muscles. Risk of hypoventilation during sleep.
Cardiac
- Conduction defects: PR interval prolongation, QRS widening, complete atrioventricular block, ventricular tachycardia. A major cause of sudden cardiac death.
- Atrial fibrillation, atrial flutter, and other supraventricular arrhythmias.
Eye
- Posterior subcapsular cataract: characteristic iridescent opacities observed on slit-lamp examination. Occurs in most adult patients.
- Ptosis, extraocular muscle paralysis.
Endocrine and metabolic
- Insulin resistance and increased incidence of diabetes.
- Male infertility: testicular atrophy, primary hypogonadism.
- Thyroid dysfunction.
Central nervous system
- Hypersomnia: daytime sleepiness unrelated to nighttime sleep. Occurs independently of sleep apnea.
- Cognitive decline: impaired executive function, attention, and visuospatial ability.
- Personality changes: apathy, avoidant tendencies.
Gastrointestinal
- Smooth muscle involvement can cause dysphagia, gastroparesis, chronic constipation, and intestinal pseudo-obstruction.
7. Signs
Myotonia-related signs
- Percussion myotonia: When the thenar muscle or tongue is tapped with a reflex hammer, relaxation after the local contraction is delayed. On percussion of the thenar muscle, thumb adduction persists for several seconds.
- Grip myotonia: Inability to release the hand after a handshake. Improves with repetition due to the warm-up phenomenon.
Signs related to weakness and muscle atrophy
- Frontal balding: early hair loss in men is characteristic.
- Characteristic 'hatchet face' due to atrophy of the temporalis and masseter.
- Ptosis, facial weakness.
- Atrophy of the sternocleidomastoid and a 'swan neck' appearance.
- Distal weakness: weakness of the wrist extensors and ankle dorsiflexors.
Cardiac signs
- ECG abnormalities: PR interval prolongation (>200 ms), left or right bundle branch block, nonspecific ST changes.
Ophthalmic signs
- Slit-lamp examination: posterior subcapsular iridescent opacities (diagnostic finding).
Laboratory findings
- Serum CK: normal or mildly elevated (more pronounced in DM2).
- Elevated fasting blood glucose, abnormal glycated hemoglobin.
- Decreased serum IgG (hypogammaglobulinemia).
- Alanine aminotransferase (ALT) and gamma-glutamyl transferase (GGT) may be mildly elevated.
8. Screening
Screening is performed when there is a family history (autosomal dominant inheritance, early cataracts, cardiac conduction disorders, myotonic symptoms) or when a characteristic clinical phenotype is observed.
- Serum CK: mild to moderate elevation; a normal CK does not exclude the diagnosis.
- Electrocardiogram (ECG): screening for conduction abnormalities. Regular testing after diagnosis is recommended even without symptoms.
- Slit-lamp examination: screening for posterior subcapsular polychromatic cataracts.
- Electromyography (EMG): myotonic discharges — a 'dive-bomber' pattern in which spontaneous action potentials repeatedly wax and wane in frequency and amplitude. Useful for both screening and diagnosis.
- Polysomnography: evaluation of sleep-related hypoventilation, sleep apnea, and central sleep disorders.
- Family history and testing of family members: screening of biological relatives is recommended to identify affected family members.
9. Diagnosis
Diagnosis is confirmed by molecular genetic testing demonstrating a repeat expansion in the DMPK or CNBP gene.
Molecular genetic testing
- DM1: triplet repeat-primed PCR (TP-PCR) combined with Southern blot. A CTG repeat count of ≥50 is the pathogenic threshold.
- DM2: CCTG repeat expansion confirmed by TP-PCR or Southern blot. Because repeat counts are very large, conventional PCR often cannot detect them. Long-read sequencing is used as an adjunct.
Ancillary diagnostic tests
- EMG: confirmation of myotonic discharges.
- Muscle MRI: assessment of the pattern of fatty infiltration of muscle (DM1: distal predominance; DM2: proximal predominance).
- Muscle biopsy: characteristic histologic findings such as internal nuclei, ring fibers, nuclear chains, and type 1 fiber atrophy.
- Cardiac evaluation: 24-hour Holter monitoring, echocardiography.
- Pulmonary function tests: forced vital capacity (FVC), maximal inspiratory pressure (MIP).
- Neuropsychological testing: assessment of cognitive function and sleep disorders.
Differential diagnosis
- Myotonia congenita (CLCN1 variants), paramyotonia (SCN4A variants), facioscapulohumeral muscular dystrophy (FSHD), limb-girdle muscular dystrophy, amyotrophic lateral sclerosis (ALS).
10. Treatment
There is currently no curative treatment; multidisciplinary symptomatic treatment and prevention of complications are the core of management.
Relief of myotonia
- Mexiletine: reduces myotonia by sodium channel blockade. Adult dose 150–200 mg two to three times daily. Caution is needed in patients with cardiac conduction disorders. Efficacy demonstrated in clinical trials (including OPTIMISTIC).
- Carbamazepine and lamotrigine may also be used as second-line options.
Cardiac management
- Cardiology consultation is essential. Regular ECG and Holter monitoring.
- With a PR interval of 300 ms or more or high-grade atrioventricular block, consider a pacemaker or implantable cardioverter-defibrillator (ICD).
Respiratory management
- Regular assessment of pulmonary function. Apply noninvasive positive pressure ventilation (BiPAP/CPAP) when FVC <50% or there are signs of nocturnal hypoventilation.
Ophthalmologic and other organ management
- For cataract surgery, plan anesthesia taking into account anesthetic risks (respiratory depression, arrhythmia).
- Diabetes screening and standard treatment. Male infertility: discuss assisted reproductive techniques.
Rehabilitation and physical therapy
- Use of ankle-foot orthoses (AFO) and walking aids.
- Low-intensity aerobic exercise helps maintain muscle strength. Overexertion should be avoided.
Treatment of hypersomnia
- Modafinil 100–200 mg/day or armodafinil may be used.
New drug development
- Antisense oligonucleotides (ASOs), small-molecule MBNL activators, and CRISPR-based therapies are in clinical trials. An ASO targeting DMPK mRNA for DM1 is in phase 1/2 clinical trials.
11. Prognosis
The prognosis of myotonic dystrophy varies greatly with disease type, age of onset, repeat size, and pattern of organ involvement. Adult-onset DM1 follows a progressive course, with gradual progression of muscle weakness and decline in respiratory function. The main causes of death are respiratory failure and sudden death from cardiac arrhythmia. According to large cohort studies, the mean age at death of patients with DM1 is significantly lower than in the general population, and cardiac-related deaths account for about 30% of all causes of death. Congenital DM1 has high perinatal mortality, and survivors often have severe intellectual disability. DM2 generally follows a milder course than adult-onset DM1, and shortening of life expectancy may be less than in DM1. However, cardiac complications also occur in DM2, so regular cardiac surveillance is essential. Systematic multidisciplinary follow-up (neurology, cardiology, pulmonology, ophthalmology, endocrinology, rehabilitation medicine) contributes to preventing complications and improving survival.
12. Prevention
Because myotonic dystrophy is a genetic disease, primary prevention is achieved through genetic counseling and preconception genetic diagnosis.
- Genetic counseling: fully explain to affected patients and families the mode of inheritance, phenotypic variability, genetic anticipation, and the risk of disease in offspring (50%).
- Preimplantation genetic testing (PGT-M): combined with in vitro fertilization, embryos are checked for repeat expansion and normal embryos are selected for transfer.
- Prenatal diagnosis: the fetal CTG/CCTG repeat count can be determined by chorionic villus sampling or amniocentesis. Fully explain to the mother that repeat size alone has limited value in predicting phenotype.
- Newborn screening: not currently included in standard newborn screening, but early diagnosis and follow-up are recommended when there is a family history.
- Prevention of complications: regular surveillance and early intervention for cardiac, respiratory, and ophthalmologic complications in diagnosed patients.
- Management of anesthetic risk: before surgery, share with the anesthesia team the risk of complications from muscle relaxants and inhaled anesthetics (respiratory depression, arrhythmia, malignant hyperthermia-like reactions). Use depolarizing muscle relaxants (succinylcholine) with caution.
13. References
- Brook JD, McCurrach ME, Harley HG, et al. Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3' end of a transcript encoding a protein kinase family member. Cell. 1992;68(4):799–808. PMID: 1310900
- Liquori CL, Ricker K, Moseley ML, et al. Myotonic dystrophy type 2 caused by a CCTG expansion in intron 1 of ZNF9. Science. 2001;293(5531):864–867. PMID: 11486088
- Thornton CA. Myotonic dystrophy. Neurol Clin. 2014;32(3):705–719. DOI: 10.1016/j.ncl.2014.04.011
- Turner C, Hilton-Jones D. The myotonic dystrophies: diagnosis and management. J Neurol Neurosurg Psychiatry. 2010;81(4):358–367. PMID: 20176601
- Udd B, Krahe R. The myotonic dystrophies: molecular, clinical, and therapeutic challenges. Lancet Neurol. 2012;11(10):891–905. PMID: 22995693
- Meola G, Cardani R. Myotonic dystrophies: an update on clinical aspects, genetic, pathology, and molecular pathomechanisms. Biochim Biophys Acta. 2015;1852(4):594–606. PMID: 25159707
- Wahbi K, Babuty D, Probst V, et al. Incidence and predictors of sudden death, major conduction defects and sustained ventricular tachyarrhythmias in 1388 patients with myotonic dystrophy type 1. Eur Heart J. 2017;38(10):751–758. PMID: 27371720
- Logigian EL, Martens WB, Moxley RT 4th, et al. Mexiletine is an effective antimyotonia treatment in myotonic dystrophy type 1. Neurology. 2010;74(18):1441–1448. PMID: 20439846
- Heatwole C, Luebbe E, Rosero S, et al. Mexiletine in myotonic dystrophy type 1: a randomized, double-blind, placebo-controlled trial. Neurology. 2021;96(2):e228–e238. PMID: 33208506
- Overby SJ, Cerro-Herreros E, Llamusi B, Artero R. RNA-mediated therapies in myotonic dystrophy. Drug Discov Today. 2018;23(12):2013–2022. PMID: 30267771